These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Tumor suppressor activity and inactivation of galanin receptor type 2 by aberrant promoter methylation in head and neck cancer. Misawa Y; Misawa K; Kanazawa T; Uehara T; Endo S; Mochizuki D; Yamatodani T; Carey TE; Mineta H Cancer; 2014 Jan; 120(2):205-13. PubMed ID: 24122450 [TBL] [Abstract][Full Text] [Related]
5. Identification of methylation markers for the prediction of nodal metastasis in oral and oropharyngeal squamous cell carcinoma. Melchers LJ; Clausen MJ; Mastik MF; Slagter-Menkema L; van der Wal JE; Wisman GB; Roodenburg JL; Schuuring E Epigenetics; 2015; 10(9):850-60. PubMed ID: 26213212 [TBL] [Abstract][Full Text] [Related]
6. Promoter hypermethylation using 24-gene array in early head and neck cancer: better outcome in oral than in oropharyngeal cancer. Noorlag R; van Kempen PM; Moelans CB; de Jong R; Blok LE; Koole R; Grolman W; van Diest PJ; van Es RJ; Willems SM Epigenetics; 2014 Sep; 9(9):1220-7. PubMed ID: 25147921 [TBL] [Abstract][Full Text] [Related]
11. Site-specific methylation patterns of the GAL and GALR1/2 genes in head and neck cancer: Potential utility as biomarkers for prognosis. Misawa K; Mochizuki D; Endo S; Mima M; Misawa Y; Imai A; Shinmura K; Kanazawa T; Carey TE; Mineta H Mol Carcinog; 2017 Mar; 56(3):1107-1116. PubMed ID: 27685843 [TBL] [Abstract][Full Text] [Related]
13. Investigation of HOXA9 promoter methylation as a biomarker to distinguish oral cancer patients at low risk of neck metastasis. Uchida K; Veeramachaneni R; Huey B; Bhattacharya A; Schmidt BL; Albertson DG BMC Cancer; 2014 May; 14():353. PubMed ID: 24886209 [TBL] [Abstract][Full Text] [Related]
14. Prognostic value of aberrant promoter hypermethylation of tumor-related genes in early-stage head and neck cancer. Misawa K; Mochizuki D; Imai A; Endo S; Mima M; Misawa Y; Kanazawa T; Carey TE; Mineta H Oncotarget; 2016 May; 7(18):26087-98. PubMed ID: 27027429 [TBL] [Abstract][Full Text] [Related]
15. Hypermethylation of collagen α2 (I) gene (COL1A2) is an independent predictor of survival in head and neck cancer. Misawa K; Kanazawa T; Misawa Y; Imai A; Endo S; Hakamada K; Mineta H Cancer Biomark; 2011-2012; 10(3-4):135-44. PubMed ID: 22674299 [TBL] [Abstract][Full Text] [Related]
16. PITX2 and PANCR DNA methylation predicts overall survival in patients with head and neck squamous cell carcinoma. Sailer V; Holmes EE; Gevensleben H; Goltz D; Dröge F; de Vos L; Franzen A; Schröck F; Bootz F; Kristiansen G; Schröck A; Dietrich D Oncotarget; 2016 Nov; 7(46):75827-75838. PubMed ID: 27716615 [TBL] [Abstract][Full Text] [Related]
17. Clinical performance validation of PITX2 DNA methylation as prognostic biomarker in patients with head and neck squamous cell carcinoma. Sailer V; Gevensleben H; Dietrich J; Goltz D; Kristiansen G; Bootz F; Dietrich D PLoS One; 2017; 12(6):e0179412. PubMed ID: 28617833 [TBL] [Abstract][Full Text] [Related]
18. Hypermethylation of promoter region of LATS1--a CDK interacting protein in oral squamous cell carcinomas--a pilot study in India. Reddy VR; Annamalai T; Narayanan V; Ramanathan A Asian Pac J Cancer Prev; 2015; 16(4):1599-603. PubMed ID: 25743838 [TBL] [Abstract][Full Text] [Related]
19. ZEB1 as an indicator of tumor recurrence for areca quid chewing-associated oral squamous cell carcinomas. Ho CM; Hu FW; Lee SS; Shieh TM; Yu CH; Lin SS; Yu CC J Oral Pathol Med; 2015 Oct; 44(9):693-8. PubMed ID: 25367287 [TBL] [Abstract][Full Text] [Related]
20. Epigenetic inactivation of galanin and GALR1/2 is associated with early recurrence in head and neck cancer. Misawa K; Misawa Y; Kanazawa T; Mochizuki D; Imai A; Endo S; Carey TE; Mineta H Clin Exp Metastasis; 2016 Feb; 33(2):187-95. PubMed ID: 26572146 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]